Skip to content

AIM Market Roundup: N4 Pharma, Future Metals, Star Energy

AIM Market Roundup: N4 Pharma, Future Metals, Star Energy

At 3pm, the AIM All Share Index was trading modestly higher on the day, broadly outperforming other indices both in London and further afield. The uptick was however limited, at just over 4 points with the index trading at 778.02 at our early copy time.

  • N4 Pharma +45%
  • Future Metals +29%
  • Star Energy +19%
  • WH Ireland -80%
  • OPG Power -18%

N4 Pharma LON:N4P was the day’s performer at copy time, trading some 45% higher. The company announced findings this morning from a research collaboration which have been seen as hugely positive in terms or targeting specific cells for lung cancer treatment.

Future Metals [LON:FME] added 29% on the day, although there’s no news in play and order flow has been lumpy. That reflects the strong start to the week seen on the stock’s Australian listing.


Star Energy [LON:STAR] gets the notable mention, up 19%. That coincides with news of a reportable stake being built up by a Swedish entity, although the scale of the purchase is closely aligned with a disposal reported at the end of last week. The spread is around 10% and volumes are far from high.

WH Ireland LON:WHI was the biggest faller down 80% at copy time after this morning’s announcement that management were seeking an orderly winding down of the business. Whilst there will be a distribution to shareholders, the company remains loss making and this is likely to be limited.

OPG Power LON:OPG was the second biggest faller, off 18%. The company advised this morning of a change in Indian tax legislation which will increase its costs by approximately £2.5m annually. With operating profits for the last financial year reported as £8.1m a few weeks ago, the impact here will be noticeable.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

eToro

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Schroders
eToro
WisdomTree
Aquis
Pepperstone

Plus500
aberdeen
CME Group
ARK
FP Markets

Back To Top